What is characteristic of the therapeutic processes in hematooncology is that new solutions, new molecules are constantly emerging. The situation of treated patients is changing, but also their needs. We are seeing a great development precisely in therapies, and there are now some that have a new mechanism of action. Please tell us more about this, about what this mechanism is and how this is changing the situation of hematooncology patients?
The question is very timely, as the European Society of Hematologists conference, where current research and changing standards of therapy were summarized, ended not long ago. Indeed, immunotherapies, for that is how broadly we can define this new group of therapeutics, are changing the reality for patients with plasma cell myeloma, chronic lymphocytic leukemia and lymphomas. In acute myeloid leukemia, this development is still slow. But let'...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
